22:00 , Jul 11, 2019 |  BC Innovations  |  Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform. Pivotal readouts in...
19:25 , Apr 19, 2019 |  BC Week In Review  |  Company News

Newer drugs lift Roche’s 1Q sales

Driven by newer drugs and expanded indications, Roche beat analyst expectations for its 1Q19 global pharmaceutical sales by 7% at CHF11.9 billion ($11.8 billion) vs. the Street's CHF11.2 billion ($11 billion) estimate. Pharmaceutical sales increased...
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
20:43 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

MacroGenics' margetuximab shows survival benefit in Phase III readout

MacroGenics Inc. (NASDAQ:MGNX) said Feb. 6 that margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a BLA submission next...
15:28 , Feb 6, 2019 |  BC Extra  |  Clinical News

Big gain for MacroGenics after breast cancer readout

MacroGenics Inc. (NASDAQ:MGNX) shares leapt Wednesday after the company said margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:45 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Dec. 17 the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes...
22:38 , Dec 17, 2018 |  BC Extra  |  Company News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Monday the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes as...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...